“But you have missed the bigger idea!\u201d exclaimed Peter Lanciano, grabbing the pepper grinder and banging it on the table. \u201cThe problem isn\u2019t how to get my drug into Mr Pepperpot. The problem is how to protect me from being sued if Mr Pepperpot dies.\u201d<\/p>\n
It had taken me two years to track Lanciano down. For this meeting I\u2019d broken off my holiday, woken up at three in the morning and flown 1,000 miles across Europe to have breakfast at a London hotel built like a penitentiary. Lanciano is the Executive Director of a small US drug company. In his early 50s, with a Teddy Roosevelt moustache and a lumberjack shirt stretched tight across his broad chest, I believe he can help solve a niggling problem that holds back medical research around the world and makes patients suffer. Every year, an untold number of potential new drugs or interventions, any one of which might go on to improve thousands of lives, are thrown away without being tested in humans. It is a matter of funding, not science: there is not enough money in the public or private sector to run clinical trials on every exciting proposal that comes out of research labs. Thoughtful but hurried (and often arbitrary) judgements are therefore made about which products to save \u2013 and the rest of these potentially life-saving therapies are ditched. \u201cThere\u2019s tons of promising stuff out there,\u201d says David Stojdl, cofounder of the Californian biotech company Jennerex Biotherapeutics, \u201cand it is dying on the vine.\u201d<\/p>\n
I have a simple proposal for a way to rescue this waste. I\u2019m not a scientist or a physician; I have no medical training. I\u2019m a biographer<\/a> and an illustrator, and until a couple of years ago I\u2019d never heard of clinical trials. But I know my idea works because I\u2019ve already tried it once, to rescue a promising anticancer therapeutic that was about to be thrown out in Sweden. The general version of my proposal has now received backing from a select group of university research departments and a clutch of experts on medical ethics, and has the interest of one of the world\u2019s largest law firms specialising in the life sciences. If the scheme can be made to work on a larger scale, it will open up the possibility of millions (I think, billions) of pounds of extra money for clinical trials, especially for rare and difficult-to-treat diseases \u2013 the ones that traditional funders are reluctant to support.<\/p>\n","protected":false},"excerpt":{"rendered":"